PKC agonism restricts innate immune suppression and promotes antigen cross-presentation in Triple Negative Breast Cancer
PKC 激动限制三阴性乳腺癌中的先天免疫抑制并促进抗原交叉呈递
基本信息
- 批准号:10387395
- 负责人:
- 金额:$ 3.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-12-20 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAntibodiesAntigen-Presenting CellsAntigensAntitumor ResponseAutomobile DrivingAwardBiological AssayBone MarrowBreast Cancer PatientCD8-Positive T-LymphocytesCancer BiologyCell CountCell Differentiation processCell physiologyCellsClinicCross PresentationCross-PrimingCytotoxic T-LymphocytesDataDatabasesDendritic CellsDependenceEquilibriumFDA approvedFamilyFrequenciesGenerationsGoalsImmuneImmunityImmunologistImmunomodulatorsImmunosuppressionImmunotherapyIn VitroInformaticsInvestigationIsoenzymesMalignant NeoplasmsMinorityModelingMonoclonal AntibodiesMyelogenousMyeloid Cell ActivationMyeloid CellsMyeloid-derived suppressor cellsNatural ImmunityPEP005PathologicPathway interactionsPatient-Focused OutcomesPatientsPharmacologyPhenotypePhosphotransferasesPlayPopulationProductionProtein IsoformsProtein Kinase CResearchResearch PersonnelResistanceRoleScienceSignal TransductionSolid NeoplasmSpleenT-LymphocyteTNFRSF5 geneTestingTherapeuticTherapeutic EffectTrainingTumor AntigensTumor BurdenTumor Immunityadaptive immunityanti-PD-L1anti-PD-L1 therapyanti-tumor immune responsebasecancer therapyconventional therapycytotoxic CD8 T cellsgenetic signatureimmune checkpoint blockadeimmunogenicimprovedin vivoinnovationloss of functionmacrophagemalignant breast neoplasmmonocytemouse modelnovelorthotopic breast cancerprogenitorprostratinprotein activationprotein expressionprotein kinase C-deltaresponsesuccesstranscription factortriple-negative invasive breast carcinomatumortumor immunologytumor microenvironmenttumor-immune system interactions
项目摘要
SUMMARY
Immune checkpoint blockade (ICB) has revolutionized cancer therapy showing unprecedented long-term
antitumor responses. However, most patients do not respond to ICB therapies due at least partly to
immunosuppression. Immunotherapy non-responders have high levels of circulating myeloid-derived suppressor
cells (MDSCs)- an immunosuppressive innate cell population that suppresses both innate and adaptive
immunity. Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancers with poor
responses to conventional therapies. TNBC patients harbor higher levels of MDSC populations compared to
non-TNBC patients. Consequently, TNBC and other solid tumor patients who have high levels of circulating
MDSCs respond poorly to ICB. Hence, strategies that reduce MDSC’s suppressive function while promoting
cross-priming of CD8+ T cells are likely to be effectively combined with ICB for a maximum therapeutic benefit.
Protein Kinase C (PKC) is a family of kinases composed of 11 isoforms that play a critical role in cell signaling.
PKC delta (PKC) is the most abundant isoform in myeloid cells and plays an important role in dendritic cell (DC)
function. To date, the role of PKC in myeloid cells in cancer is unknown. Using varied informatic approaches in
patient databases, I found that BC patients with both high expression of PRKCD and either high expression of
CD8+ T cell or low expression of MDSC gene signatures in tumors had a significantly greater overall survival
compared to other groups, suggesting support for activation of PKC. Novel preliminary data suggests that PKC
agonism using FDA-approved PEP005 and prostratin reduced MDSC generation from bone marrow progenitors
specifically via activation of PKC isoform. PKC agonism induced MDSC differentiation to CD103+ DC-like cells
both ex-vivo and in vivo. Additionally, PEP005-treated MDSCs lost their suppressive capacity on CD8+ T cells in
both in vitro and in vivo pilot suppression assays and efficiently cross-primed OT-I CD8+ T cells. Mechanistic
studies reveal transcription factor IRF5 as a potential target of PKC-to be explored in this proposal. Based on
rigorously generated pilot data, I hypothesize that PKC agonism combined with agonistic CD40 mAb will
sensitize TNBC tumors to ICB through induced differentiation of MDSCs to DC-like cells via activation of PKC
and its downstream target IRF5. CD40 is mainly expressed by myeloid cells and its activation has been shown
to effectively activate antigen-presenting cells. Aim 1 & 2 will determine if PKC activation controls MDSC and
DC phenotype and function and will determine to what extent pharmacologic activation of PKC in combination
with agonistic CD40 mAb improves anti-PD-L1 therapy in TNBC mouse models. The proposed training will
prepare me for my long-term goal of becoming a tumor immunologist with a research objective to develop novel
immunomodulatory therapeutic approaches against solid tumors as an independent investigator.
总结
免疫检查点阻断(ICB)彻底改变了癌症治疗,显示出前所未有的长期疗效。
抗肿瘤反应。然而,大多数患者对ICB治疗没有反应,至少部分原因是
免疫抑制免疫治疗无应答者的循环髓源性抑制因子水平较高
细胞(MDSC)-一种免疫抑制性先天细胞群,抑制先天和适应性
免疫力三阴性乳腺癌(TNBC)是乳腺癌中最具侵袭性的亚型,具有较差的免疫原性。
对常规治疗的反应。TNBC患者具有更高水平的MDSC群体,
非TNBC患者。因此,TNBC和其他具有高水平循环肿瘤的实体瘤患者,
MDSC对ICB反应较差。因此,降低MDSC的抑制功能同时促进MDSC表达的策略是可行的。
CD 8 + T细胞的交叉致敏可能与ICB有效地组合以获得最大的治疗益处。
蛋白激酶C(PKC)是一个由11种亚型组成的激酶家族,在细胞信号传导中起关键作用。
蛋白激酶C δ(PKC δ)是髓系细胞中含量最丰富的一种亚型,在树突状细胞(DC)中起重要作用
功能迄今为止,PKC β在骨髓细胞中的作用在癌症中是未知的。使用各种信息方法,
患者数据库中,我发现BC患者既有PRKCD的高表达,
肿瘤中CD 8 + T细胞或MDSC基因标签的低表达具有显著更高的总生存率。
与其他组相比,提示支持PKC β的激活。新的初步数据表明,PKC
使用FDA批准的PEP 005和prostratin的激动作用减少了骨髓祖细胞的MDSC生成
特别是通过激活PKC β亚型。PKC激动诱导MDSC向CD 103 + DC样细胞分化
包括离体和体内。此外,PEP 005处理的MDSC丧失了对CD 8 + T细胞的抑制能力,
体外和体内试验性抑制测定和有效交叉致敏的OT-I CD 8 + T细胞。机械论
研究表明转录因子IRF 5是PKC β的潜在靶点-在本研究中有待探索。基于
严格生成的试验数据,我假设PKC激动剂与激动性CD 40 mAb联合使用,
通过活化PKC β 1诱导MDSC分化为DC样细胞,使TNBC肿瘤对ICB敏感
及其下游靶点IRF 5。CD 40主要由骨髓细胞表达并已显示其激活
以有效地激活抗原呈递细胞。目的1和2将确定PKC β 1激活是否控制MDSC,
DC的表型和功能,并将决定在何种程度上的药理学激活PKC的组合
与激动性CD 40 mAb联合使用改善了TNBC小鼠模型中的抗PD-L1治疗。拟议的培训将
为我成为一名肿瘤免疫学家的长期目标做好准备,
作为独立研究者,研究针对实体瘤的免疫调节治疗方法。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mehdi Chaib其他文献
Mehdi Chaib的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 3.28万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 3.28万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 3.28万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 3.28万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 3.28万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 3.28万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 3.28万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 3.28万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 3.28万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 3.28万 - 项目类别: